Cargando…

P17-15. Immunogenicity studies of chimeric yellow fever 17D viruses carrying HIV-1 p24 antigen

Detalles Bibliográficos
Autores principales:	Franco, D, Rosas, C, Rice, CM, Ho, DD
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767800/ http://dx.doi.org/10.1186/1742-4690-6-S3-P297

Ejemplares similares

Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice
por: Ma, Ji, et al.
Publicado: (2021)

A Yellow Fever Virus 17D Infection and Disease Mouse Model Used to Evaluate a Chimeric Binjari-Yellow Fever Virus Vaccine
por: Yan, Kexin, et al.
Publicado: (2020)

17D Yellow Fever Virus Vaccine
por: Monath, Thomas P.
Publicado: (2013)

Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone
por: Touret, Franck, et al.
Publicado: (2018)

Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine
por: Giel-Moloney, Maryann, et al.
Publicado: (2018)

17DD yellow fever vaccine: A double blind, randomized clinical trial of immunogenicity and safety on a dose-response study
por: Martins, Reinaldo M., et al.
Publicado: (2013)

Dissolving mechanism of strain P17 on insoluble phosphorus of yellow-brown soil
por: Chuan-qing, Zhong, et al.
Publicado: (2014)

Is a dose of 17D vaccine in the current context of Yellow Fever enough?
por: Estofolete, Cassia Fernanda, et al.
Publicado: (2018)

Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes
por: Barba-Spaeth, Giovanna, et al.
Publicado: (2005)

Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model
por: Tao, Deng, et al.
Publicado: (2005)

Immunogenicity of Seven New Recombinant Yellow Fever Viruses 17D Expressing Fragments of SIVmac239 Gag, Nef, and Vif in Indian Rhesus Macaques
por: Martins, Mauricio A., et al.
Publicado: (2013)

Description of a Prospective 17DD Yellow Fever Vaccine Cohort in Recife, Brazil
por: de Melo, Andréa Barbosa, et al.
Publicado: (2011)

Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees
por: Mateus, Jose, et al.
Publicado: (2020)

Limited evolution of the yellow fever virus 17d in a mouse infection model
por: Kum, Dieudonné Buh, et al.
Publicado: (2019)

Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine
por: Wec, Anna Z., et al.
Publicado: (2020)

Yellow Fever Vaccine-Related Neurotropic Disease in Brazil Following Immunization with 17DD
por: de Andrade Gandolfi, Flora, et al.
Publicado: (2023)

Fractional Dosing of Yellow Fever Live Attenuated 17D Vaccine: A Perspective
por: Hansen, Clairissa A, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV
por: Motta, Edwiges, et al.
Publicado: (2023)

17DD and 17D-213/77 Yellow Fever Substrains Trigger a Balanced Cytokine Profile in Primary Vaccinated Children
por: Campi-Azevedo, Ana Carolina, et al.
Publicado: (2012)

P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
por: Rolland, MM, et al.
Publicado: (2009)

Kinetic Study of Yellow Fever 17DD Viral Infection in Gallus gallus domesticus Embryos
por: Manso, Pedro Paulo de Abreu, et al.
Publicado: (2016)

Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline
por: Campi-Azevedo, Ana Carolina, et al.
Publicado: (2014)

Yellow Fever 17DD Vaccine Virus Infection Causes Detectable Changes in Chicken Embryos
por: Manso, Pedro Paulo de Abreu, et al.
Publicado: (2015)

Anterograde Transneuronal Tracing and Genetic Control with Engineered Yellow Fever Vaccine YFV-17D
por: Li, Elizabeth, et al.
Publicado: (2021)

A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses
por: Oreshkova, Nadia, et al.
Publicado: (2021)

Evaluation of Two Adjuvant Formulations for an Inactivated Yellow Fever 17DD Vaccine Candidate in Mice
por: Cajaraville, Ana Carolina dos Reis Albuquerque, et al.
Publicado: (2022)

A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice
por: Kum, Dieudonné Buh, et al.
Publicado: (2020)

A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination
por: Wieten, Rosanne W., et al.
Publicado: (2016)

Runs 22, 23, 24, 25 on February 12, 15 and 17 1971
por: Knezovic, A, et al.
Publicado: (1971)

Single shot of 17D vaccine may not confer life-long protection against yellow fever
por: Vasconcelos, Pedro FC
Publicado: (2017)

A large fraction of trisomy 12, 17p(−), and 11q(−) CLL cases carry unidentified microdeletions of miR-15a/16-1
por: Pepe, Felice, et al.
Publicado: (2022)

P17. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells
por: Schnurr, M, et al.
Publicado: (2014)

The immunogenicity of chimeric antibodies
Publicado: (1989)

Study of the $^{15}$O$(2p,\gamma )^{17}$Ne Cross Section by Coulomb Dissociation of $^{17}$Ne for the $rp$ Process of Nucleosynthesis
por: Marganiec, J, et al.
Publicado: (2014)

Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice
por: Bassi, Maria R., et al.
Publicado: (2016)

17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil
por: Campi-Azevedo, Ana Carolina, et al.
Publicado: (2019)

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study
por: Tricou, Vianney, et al.
Publicado: (2023)

Miller-Dieker Syndrome with der(17)t(12;17)(q24.33;p13.3)pat Presenting with a Potential Risk of Mis-identification as a de novo Submicroscopic Deletion of 17p13.3
por: Kim, Young Jin, et al.
Publicado: (2011)

Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities
Publicado: (1991)

Characterization of a Novel Chimeric Theileria parva p67 Antigen Which Incorporates into Virus-like Particles and Is Highly Immunogenic in Mice
por: Whittle, Leah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u31h0f90mnth52kstps62kj6s8